Posted inClinical Updates news Oncology Specialties
Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study
FT516, an iPSC-derived NK cell therapy, shows promising safety and efficacy in relapsed or refractory B-cell lymphoma, potentially overcoming key limitations of existing cell therapies.